Table 3.
Variable | Coefficient (β) | SE | P-value |
---|---|---|---|
Intercept | 2.60 | 0.28 | <0.001 |
Treatment (DOX alone versus DEX+DOX) | 0.46 | 0.13 | 0.001 |
Sex (male versus female) | 0.11 | 0.14 | 0.45 |
Agea (<10 versus ≥10 years) | 0.02 | 0.14 | 0.89 |
Immunophenotype (B-cell versus T-cell) | -0.18 | 0.21 | 0.41 |
RBC contamination (no versus yes) | 0.02 | 0.14 | 0.89 |
Initial WBC | -0.0006 | 0.001 | 0.60 |
Age at the time of protocol registration.
DOX, doxorubicin; DEX, dexrazoxane; DEX+DOX, administration of dexrazoxane prior to every doxorubicin treatment; RBC, red blood cell; SE, standard error; WBC, white blood cell count.